Table 4 Treatment responses according to treatment modality and type of plasma cell-proliferative disorder
From: The role of radiotherapy in the management of POEMS syndrome
Feature | No. of Pts, | Clinical response | Hematologic response | ||||||
|---|---|---|---|---|---|---|---|---|---|
No. of patients (%) | No. of patients (%) | ||||||||
Improved | Mixed | Stable | Progression | CR H | VGPR H | PR H | NR H | ||
RT | 4 | 3 (75) | 0 (0) | 1 (25) | 0 (0) | 1 (25) | 1 (25) | 0 (0) | 2 (50) |
CHT | 16 | 11 (69) | 1 (6) | 2 (13) | 2 (13) | 5 (31) | 2 (13) | 4 (25) | 5 (31) |
RT + CHT | 9 | 8 (89) | 0 (0) | 0 (0) | 1 (11) | 4 (44) | 1 (11) | 1 (11) | 3 (33) |
Steroid or Ig | 4 | 1 (25) | 1 (25) | 1 (25) | 1 (25) | 0 (0) | 0 (0) | 0 (0) | 4 (100) |
OSM | 13 | 11 (84) | 0 (0) | 1 (8) | 1 (8) | 6 (46) | 1 (8) | 3 (23) | 3 (23) |
CD | 4 | 2 (50) | 0 (0) | 1 (25) | 1 (25) | 0 (0) | 1 (25) | 2 (50) | 1 (25) |
OSM + CD | 10 | 7 (70) | 1 (10) | 1 (10) | 1 (10) | 3 (30) | 2 (20) | 0 (0) | 5 (50) |
VEGFe | 6 | 3 (50) | 1 (17) | 1 (17) | 1 (17) | 1 (17) | 0 (0) | 0 (0) | 5 (83) |